Astellas has said it will book a $170 million impairment charge in its fourth quarter results as a result of a decision to halt the development of three ... along with DMD gene therapies AT702, ...

Pompe Disease Market Insight - DelveInsightThe Pompe disease treatment market is experiencing significant expansion, driven by increasing di ...

With the safety of gene therapies thrown into the spotlight by a series of FDA clinical holds, Astellas has said that an interim readout in a phase 1/2 trial of its Pompe disease candidate AT845 ...

Gene therapies, exon-skipping drugs and next-gen steroids are reshaping Duchenne muscular dystrophy care, targeting broader ages and mutations. We are witnessing the fastest pivot in rare-disease ...

JMP Securities Silvan Tuerkcan revised the firm’s view on Taysha Gene Therapies, Inc. (NASDAQ:TSHA), raising the price target from $5 to $6 while keeping a Market Outperform rating. The update ...

BOSTON & MONTREAL, June 12, 2025--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced its financial results for ...

Market is one of the leading causes of irreversible vision loss in individuals aged 50 and above. With the global aging population increasing rapidly, the burden of AMD is escalating, pushing the ...

Today, a brief rundown of news involving Astellas Pharma and Keros Therapeutics, as well as updates from Stealth Biotherapeutics, PepGen and Taysha Gene Therapies that you may have missed. Keros ...

Taysha Gene Therapies, Inc. announced the granting of stock options to two new employees, totaling 401,000 shares of common stock, as part of their employment package. These options were granted ...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA)’s pivotal Part B trial, expected to launch in Q3 2025, will enroll 15 females in the developmental plateau stage, using each patient as their own ...